Cantitate/Preț
Produs

Understanding Cancer from a Systems Biology Point of View: From Observation to Theory and Back

Autor Irina Kareva
en Limba Engleză Paperback – 7 feb 2018
Understanding Cancer from a Systems Biology Point of View: From Observation to Theory and Back starts with a basic question, why do we sometimes observe accelerated metastatic growth after resection of primary tumors? Next, it helps readers understand the systemic nature of cancer and how it affects treatment approaches and decisions. The book puts together aspects of cancer that many readers have most likely never combined, using unfamiliar, novel methods. It is a valuable resource for cancer researchers, cancer biologists, mathematicians and members of the biomedical field who are interested in applying systems biology methodologies for understanding and treating cancer.


  • Explains the systemic nature of cancer and how it affects decisions on treatment
  • Brings a variety of methods together, showing, in detail, the logical approach to finding answers to complex questions
  • Discusses the theoretical underpinnings of cancer as a systemic disease, providing the reader with valuable information on applicable cases
Citește tot Restrânge

Preț: 71232 lei

Preț vechi: 90448 lei
-21% Nou

Puncte Express: 1068

Preț estimativ în valută:
13636 14024$ 11313£

Carte tipărită la comandă

Livrare economică 11-25 februarie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780128136737
ISBN-10: 0128136731
Pagini: 118
Dimensiuni: 152 x 229 x 11 mm
Greutate: 0.2 kg
Editura: ELSEVIER SCIENCE

Public țintă

cancer researchers;cancer biologists;mathematicians;systems biologists

Cuprins

1. Introduction2. Tumor dormancy3. Cancer immunoediting: a process driven by metabolic competition as a predator-prey-shared resource type model4. Escape from tumor dormancy and time to angiogenic switch as mitigated by tumor- induced stimulation of stroma5. Angiogenesis regulators as a possible key to accelerated growth of secondary tumors following primary tumor resection6. A combination of immune checkpoint inhibition with metronomic chemotherapy as a way of targeting therapy-resistant cancer cells7. Summary and conclusions